Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

he treatment of depression," said Mr. Howard-Tripp. "Trazodone has a proven history of efficacy and we believe that by controlling the blood concentration levels through our Contramid(R) controlled-release technology, we can offer a once-daily formulation with a potentially improved side effect profile that takes advantage of trazodone's unique sedative effects, eliminating the need for adjunctive therapy often associated with other anti-depressants to address related conditions such as poor sleep quality. We look forward to reporting data from our Phase III study in the second quarter of next year."

Other Development Programs

Labopharm continues to advance the development programs for other product candidates in its pipeline, including its programs to develop a twice-daily tramadol-acetaminophen combination formulation and a twice-daily acetaminophen formulation, both of which are based on the Company's proprietary Contramid(R) technology. The Company is currently in the process of preparing for pivotal studies for the tramadol-acetaminophen formulation, which it expects to begin imminently.

Financial Results

Revenue for the third quarter of fiscal 2007 increased to $5.1 million from $3.3 million for the third quarter of fiscal 2006. Product sales increased to $2.8 million from $1.1 million with the increase being the result of higher volumes due to shipments of once-daily tramadol to a larger number of markets in the third quarter of fiscal 2007 compared to the third quarter of fiscal 2006, as well as higher average selling prices in the third quarter of fiscal 2007, primarily as a result of launch of the product in Canada, where selling prices are higher than in Europe. Product sales for the third quarter of fiscal 2007 consisted of follow-on shipments of once-daily tramadol to our marketing partners in Europe for distribution in various markets, as well as initial shipments to Paladin Labs Inc. for distribution in Canada.

Gross marg
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Wellesley, Mass., September ... in its new report, Joint Reconstruction and ... market for joint reconstruction and replacement is expected to ... compound annual growth rate (CAGR) of 4.2% from 2013 ... the major regions, surging at a CAGR of 5.1%. ...
(Date:9/23/2014)... 2014 Given the nondiscretionary nature ... Fruit and Vegetable Markets industry is generally ... benefited operators over the five years to 2014. ... and demographic trends, including a focus on healthy ... capita fruit and vegetable consumption declined at an ...
(Date:9/23/2014)... "area under the curve of oxygen desaturation" (AUC Desat ... blood oxygen levels during procedures using sedation, according to ... , The AUC Desat provides information not only ... the depth, duration, and rate of episodes of oxygen ... of University of Cincinnati and colleagues reports on the ...
(Date:9/23/2014)... cancer in their lifetime and 20 per cent of ... researchers from the University of Leicester has helped Avacta ... system for diagnosing lymphoma in dogs in the early ... cLBT (canine lymphoma blood test), this is the first ... status of a dog after undergoing chemotherapy. , ...
(Date:9/23/2014)... NEW YORK, NY (PRWEB) September 23, 2014 ... the best innovators in the pharmaceutical industry with their ... honors, bestowed at a gala banquet at Gotham Hall ... marketers and brand managers representing top talent and brands. ... to celebrate its accomplishments,” says Anna Stashower, CEO and ...
Breaking Medicine News(10 mins):Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New hope for beloved family pets 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6
... POTOMAC FALLS, Va., Nov. 3 "When my father ... read every book,pamphlet, and newspaper article I could get ... book, "A Conversation About Alzheimer,s" (published by,AuthorHouse -- ... think about. I told myself that once I knew ...
... more common for adolescents illegally at the wheel, study finds, ... the thought of teenagers driving before they,ve gotten their license ... are also more likely to drive while drinking or on ... get behind the wheel. , Reporting in the November issue ...
... JOHNSON,S(R) Partners With MARCH OF DIMES(R) To Build ... The United States, SKILLMAN, N.J., Nov. 3 ... of "Prematurity Awareness Month" that partners,with the March ... growing problem of,premature birth and raise funds to ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (Nasdaq: CHBT ) ... the research, development, manufacture, marketing and,distribution of probiotics ... call at 9:00 a.m. EST on Tuesday, November ... the second quarter ended,September 30, 2008, of its ...
... Nov. 3 Hooper Holmes,(Amex: HH ) today ... before market on Friday, November 7, 2008. The Company,will ... at 11:00am Eastern,Time., Conference Call, To participate ... code: Hooper Holmes. A live web cast will be ...
... Inc. (Nasdaq: MBRK ), a pharmaceutical ... products, today,announced that it has retained national ... will serve as MiddleBrook,s strategic and tactical ... reimbursement, contract,administration, national account management and government ...
Cached Medicine News:Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Many Unlicensed Teen Drivers Put Safety Last 2Health News:Many Unlicensed Teen Drivers Put Safety Last 3Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 2Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 3Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 3Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, ... announced the formation of the DripDrop Foundation, with ... preventable dehydration worldwide. Utilizing scientific advancements in Oral ... solutions to reduce dehydration and healthcare costs through ... missions. "DripDrop has been used ...
(Date:9/23/2014)... Wash. , Sept. 23, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... two new additions to its Scientific Advisory Board.  The ... Anthony Davies , PhD. Dr. Acker ...
(Date:9/22/2014)... -- , La tecnología basada en ... satisfagan el creciente rigor de las autoridades sanitarias en ... permanentes de ensayo (TMF, por sus siglas en inglés) ... el sector de las ciencias biológicas hasta la fecha ... ensayos clínicos que planean proporcionar a los auditores acceso ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... April 19, 2011 Genetic Technologies Limited ... preliminary research collaboration agreement to jointly develop a new ... pharmaceutical companies. Under the collaboration Genetic ... work with this world-leading pharmaceutical company to develop specific ...
... April 19, 2011 If your medicine has expired, ... this Consumer Update video, FDA pharmacist Ilisa Bernstein explains ... to use and will work as intended. ... http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251658.htm Sign up for e-mail notices ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
... of rubella IgG antibody in women prior ... from possible rubella viral infection during pregnancy. ... greatly reduced the incidence of rubella epidemics, ... monitoring of immune status, especially for women ...
... IgG antibody in women prior to conception ... rubella viral infection during pregnancy. Aggressive ... the incidence of rubella epidemics, but a ... immune status, especially for women of child-bearing ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
Medicine Products: